Journal article
Classes of therapeutics to amplify the immune response
Breast cancer research and treatment, Vol.191(2), pp.277-289
01/2022
DOI: 10.1007/s10549-021-06369-3
PMCID: PMC11646685
PMID: 34787761
Abstract
Conventional chemotherapies are a mainstay for metastatic breast cancers, though durable response is rare. Immunotherapies promise long-term responses thorough immune activation but have been underwhelming in breast cancer relative to other cancer types. Here, we review the mechanisms of existing strategies including chemotherapies and how they may cause breast cancers to become immunogenic to identify potential biomarkers for combinations of conventional and immunotherapies.
Mechanistic considerations should inform biomarker development and patient selection for therapeutic combinations of drugs to combine with immune-checkpoint inhibitors.
Details
- Title: Subtitle
- Classes of therapeutics to amplify the immune response
- Creators
- Yang Hu - University of Wisconsin–MadisonMark E Burkard - University of Wisconsin–Madison
- Resource Type
- Journal article
- Publication Details
- Breast cancer research and treatment, Vol.191(2), pp.277-289
- DOI
- 10.1007/s10549-021-06369-3
- PMID
- 34787761
- PMCID
- PMC11646685
- NLM abbreviation
- Breast Cancer Res Treat
- ISSN
- 0167-6806
- eISSN
- 1573-7217
- Grant note
- T32 GM008692 / NIGMS NIH HHS T32 GM140935 / NIGMS NIH HHS P30 CA014520 / NCI NIH HHS R01 CA234904 / NCI NIH HHS
- Language
- English
- Date published
- 01/2022
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984700655802771
Metrics
11 Record Views